Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

133

Participants

Timeline

Start Date

December 22, 2021

Primary Completion Date

June 30, 2024

Study Completion Date

December 31, 2024

Conditions
Triple-negative Breast CancerHead and Neck Squamous Cell Carcinoma
Interventions
BIOLOGICAL

TJ107 +Pembrolizumab

TJ107 injection:1200ug/Kg, Q12W, IM; Pembrolizumab: 200mg, Q3W, IV

Trial Locations (20)

100021

Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

Unknown

The First Affiliated Hospital of Anhui Medical University, Hefei

The Second Hospital of Anhui Medical University, Hefei

Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen

Hainan General Hospital, Haikou

Harbin Medical University Cancer Hospital, Harbin

Hubei Cancer Hospital, Wuhan

Tongji Hospital, Tongji Medical College of Huzhong University of Science and Technology, Wuhan

The Second Xiangya Hospital of Central South University, Changsha

Jilin Cancer Hospital, Changchun

Jilin Guowen Hospital, Changchun

The First Hospital of Jilin University, Changchun

Yanbian University Hospital, Yanji

The First Hospital of China Medical University, Shenyang

Fudan University Shanghai Cancer Center, Shanghai

Shanghai East Hospital, Shanghai

Shanghai Ninth People's Hospital,Shanghai Jiaotong University School of Medicine, Shanghai

Tianjin Medical University Cancer Institute & Hospital, Tianjin

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
lead

TJ Biopharma Co., Ltd.

INDUSTRY